Beinke Sören, Ley Steven C
Division of Immune Cell Biology, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK.
Biochem J. 2004 Sep 1;382(Pt 2):393-409. doi: 10.1042/BJ20040544.
Two members of the NF-kappaB (nuclear factor kappaB)/Rel transcription factor family, NF-kappaB1 and NF-kappaB2, are produced as precursor proteins, NF-kappaB1 p105 and NF-kappaB2 p100 respectively. These are proteolytically processed by the proteasome to produce the mature transcription factors NF-kappaB1 p50 and NF-kappaB2 p52. p105 and p100 are known to function additionally as IkappaBs (inhibitors of NF-kappaB), which retain associated NF-kappaB subunits in the cytoplasm of unstimulated cells. The present review focuses on the latest advances in research on the function of NF-kappaB1 and NF-kappaB2 in immune cells. NF-kappaB2 p100 processing has recently been shown to be stimulated by a subset of NF-kappaB inducers, including lymphotoxin-beta, B-cell activating factor and CD40 ligand, via a novel signalling pathway. This promotes the nuclear translocation of p52-containing NF-kappaB dimers, which regulate peripheral lymphoid organogenesis and B-lymphocyte differentiation. Increased p100 processing also contributes to the malignant phenotype of certain T- and B-cell lymphomas. NF-kappaB1 has a distinct function from NF-kappaB2, and is important in controlling lymphocyte and macrophage function in immune and inflammatory responses. In contrast with p100, p105 is constitutively processed to p50. However, after stimulation with agonists, such as tumour necrosis factor-alpha and lipopolysaccharide, p105 is completely degraded by the proteasome. This releases associated p50, which translocates into the nucleus to modulate target gene expression. p105 degradation also liberates the p105-associated MAP kinase (mitogen-activated protein kinase) kinase kinase TPL-2 (tumour progression locus-2), which can then activate the ERK (extracellular-signal-regulated kinase)/MAP kinase cascade. Thus, in addition to its role in NF-kappaB activation, p105 functions as a regulator of MAP kinase signalling.
核因子κB(NF-κB)/Rel转录因子家族的两个成员,即NF-κB1和NF-κB2,最初是以前体蛋白形式产生的,分别为NF-κB1 p105和NF-κB2 p100。这些前体蛋白经蛋白酶体进行蛋白水解加工,产生成熟的转录因子NF-κB1 p50和NF-κB2 p52。已知p105和p100还可作为IκB(NF-κB抑制剂)发挥作用,它们在未受刺激的细胞胞质中保留相关的NF-κB亚基。本综述聚焦于NF-κB1和NF-κB2在免疫细胞中功能的研究最新进展。最近研究表明,NF-κB2 p100的加工可被包括淋巴毒素-β、B细胞活化因子和CD40配体在内的一部分NF-κB诱导剂通过一条新的信号通路所刺激。这促进了含p52的NF-κB二聚体的核转位,其可调节外周淋巴器官的发生和B淋巴细胞的分化。p100加工增加也促成了某些T细胞和B细胞淋巴瘤的恶性表型。NF-κB1具有与NF-κB2不同的功能,在免疫和炎症反应中控制淋巴细胞和巨噬细胞功能方面很重要。与p100不同,p105可组成性地加工为p50。然而,在用诸如肿瘤坏死因子-α和脂多糖等激动剂刺激后,p105会被蛋白酶体完全降解。这会释放相关的p50,其转位进入细胞核以调节靶基因表达。p105的降解还会释放与p105相关的丝裂原活化蛋白激酶(MAP激酶)激酶激酶TPL-2(肿瘤进展位点-2),然后它可激活细胞外信号调节激酶(ERK)/MAP激酶级联反应。因此,除了其在NF-κB激活中的作用外,p105还作为MAP激酶信号传导的调节因子发挥作用。